Vilip
Generic Name
Vildagliptin
Manufacturer
A leading pharmaceutical company
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| vilip 50 mg tablet | ৳ 19.00 | ৳ 190.00 |
Description
Overview of the medicine
Vilip 50 mg Tablet contains Vildagliptin, an oral antidiabetic drug used to improve glycemic control in adult patients with type 2 diabetes mellitus. It is used as monotherapy or in combination with other antidiabetic agents when diet and exercise alone do not provide adequate glycemic control.
Uses & Indications
Dosage
Adults
The recommended dose is 50 mg or 100 mg daily. For monotherapy or in combination with metformin, a thiazolidinedione, or insulin, the dose is 50 mg or 100 mg daily. When used in dual combination with a sulfonylurea, the recommended dose is 50 mg once daily.
Elderly
No dose adjustment is required in elderly patients. However, renal function should be assessed before initiating treatment.
Renal_impairment
In patients with moderate or severe renal impairment (eGFR <50 mL/min) or End-Stage Renal Disease (ESRD) on hemodialysis, the recommended dose is 50 mg once daily.
How to Take
Take Vilip 50 mg Tablet orally, with or without food. It can be taken in the morning, and if prescribed twice daily, one in the morning and one in the evening.
Mechanism of Action
Vildagliptin is a potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor. By inhibiting DPP-4, Vildagliptin prevents the rapid degradation of incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). This leads to increased fasting and postprandial endogenous levels of GLP-1 and GIP, enhancing glucose-dependent insulin secretion from pancreatic beta cells and decreasing glucagon secretion from pancreatic alpha cells. This results in improved glycemic control.
Pharmacokinetics
Onset
Within hours of administration, with effects on glucose metabolism observable shortly after.
Excretion
Approximately 85% of the dose is excreted in the urine, with about 15% excreted in the feces. Renal excretion of unchanged drug is minimal.
Half life
Approximately 2 to 3 hours, but its pharmacodynamic effect (DPP-4 inhibition) lasts longer, allowing once or twice daily dosing.
Absorption
Rapidly absorbed after oral administration, with peak plasma concentrations occurring 1.5 to 2 hours post-dose. Absolute oral bioavailability is 85%.
Metabolism
Primarily hydrolyzed by the enzyme N-dehydropyrimidinyl to form an inactive main metabolite. Minimal involvement of cytochrome P450 enzymes.
Side Effects
Contraindications
- Hypersensitivity to the active substance or to any of the excipients
- Type 1 Diabetes Mellitus
- Diabetic ketoacidosis
- Severe hepatic impairment
Drug Interactions
ACE inhibitors
Increased risk of angioedema when co-administered with ACE inhibitors.
Thiazides, Corticosteroids, Thyroid products, Sympathomimetics
May reduce the glucose-lowering effect of Vildagliptin.
Storage
Store below 30°C in a dry place, protected from light and moisture. Keep out of reach of children.
Overdose
Experience with Vildagliptin overdose is limited. Symptoms observed included muscle pain, mild and transient paraesthesia, fever, edema. In case of overdose, supportive treatment should be initiated as dictated by the patient’s clinical status.
Pregnancy & Lactation
Vildagliptin is not recommended during pregnancy and in women of childbearing potential not using contraception. It is not known whether Vildagliptin is excreted in human milk, therefore, it should not be used during breastfeeding.
Side Effects
Contraindications
- Hypersensitivity to the active substance or to any of the excipients
- Type 1 Diabetes Mellitus
- Diabetic ketoacidosis
- Severe hepatic impairment
Drug Interactions
ACE inhibitors
Increased risk of angioedema when co-administered with ACE inhibitors.
Thiazides, Corticosteroids, Thyroid products, Sympathomimetics
May reduce the glucose-lowering effect of Vildagliptin.
Storage
Store below 30°C in a dry place, protected from light and moisture. Keep out of reach of children.
Overdose
Experience with Vildagliptin overdose is limited. Symptoms observed included muscle pain, mild and transient paraesthesia, fever, edema. In case of overdose, supportive treatment should be initiated as dictated by the patient’s clinical status.
Pregnancy & Lactation
Vildagliptin is not recommended during pregnancy and in women of childbearing potential not using contraception. It is not known whether Vildagliptin is excreted in human milk, therefore, it should not be used during breastfeeding.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 24 to 36 months from the date of manufacture, refer to the product packaging for exact date.
Availability
Available in pharmacies and hospitals
Approval Status
Approved (internationally since 2007, locally varies)
Patent Status
Generic versions available
Clinical Trials
Vildagliptin has undergone extensive clinical trials demonstrating its efficacy and safety in patients with type 2 diabetes mellitus, both as monotherapy and in combination with other antidiabetic agents.
Lab Monitoring
- HbA1c levels (regularly)
- Renal function (eGFR) before and during treatment
- Liver enzyme levels (ALT/AST) periodically, especially before starting treatment and if symptoms of liver injury develop
Doctor Notes
- Assess renal function before initiating treatment and periodically thereafter.
- Monitor liver enzymes (ALT/AST) before treatment, at 3-month intervals for the first year, and periodically thereafter, or if liver dysfunction is suspected.
- Caution with patients having a history of pancreatitis.
- Consider dose adjustment in patients with moderate to severe renal impairment.
Patient Guidelines
- Take the tablet at the same time each day.
- Do not stop taking Vilip without consulting your doctor.
- Follow your prescribed diet and exercise program.
- Be aware of symptoms of hypoglycemia, especially if taking with sulfonylurea or insulin.
- Report any unusual or severe side effects to your doctor.
Missed Dose Advice
If you miss a dose of Vilip, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and resume your regular dosing schedule. Do not double the dose to catch up.
Driving Precautions
Vilip has no or negligible influence on the ability to drive and use machines. However, patients experiencing dizziness should be cautious. If used in combination with a sulfonylurea or insulin, the risk of hypoglycemia may increase, which can impair driving ability.
Lifestyle Advice
- Maintain a healthy and balanced diet.
- Engage in regular physical activity as advised by your healthcare provider.
- Monitor your blood glucose levels regularly as instructed.
- Maintain a healthy body weight.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.